Market Closed -
Nasdaq Stockholm
06:18:28 2024-04-30 am EDT
|
5-day change
|
1st Jan Change
|
0.17
SEK
|
+4.29%
|
|
+6.25%
|
+57.41%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
312.6
|
349.2
|
372
|
437.6
|
324.6
|
58.92
|
Enterprise Value (EV)
1 |
297.3
|
323.1
|
364.4
|
401.5
|
290.6
|
57.65
|
P/E ratio
|
-46.9
x
|
-90.5
x
|
-15.4
x
|
-12.3
x
|
-8.2
x
|
-1.58
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
304
x
|
45
x
|
-
|
1,268
x
|
91.3
x
|
31.2
x
|
EV / Revenue
|
289
x
|
41.7
x
|
-
|
1,164
x
|
81.8
x
|
30.5
x
|
EV / EBITDA
|
-
|
-292,159,575
x
|
-28,077,641
x
|
-12,611,686
x
|
-7,895,438
x
|
-1,595,580
x
|
EV / FCF
|
-13.3
x
|
-13.9
x
|
-12.6
x
|
-20.9
x
|
-9.34
x
|
-2.55
x
|
FCF Yield
|
-7.5%
|
-7.19%
|
-7.93%
|
-4.78%
|
-10.7%
|
-39.2%
|
Price to Book
|
2.46
x
|
2.2
x
|
2.5
x
|
10.2
x
|
6.69
x
|
3.84
x
|
Nbr of stocks (in thousands)
|
20,981
|
23,051
|
23,692
|
29,667
|
33,990
|
34,740
|
Reference price
2 |
14.90
|
15.15
|
15.70
|
14.75
|
9.550
|
1.696
|
Announcement Date
|
4/25/18
|
4/25/19
|
4/22/20
|
4/16/21
|
4/26/22
|
4/25/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
1.029
|
7.755
|
-
|
0.345
|
3.554
|
1.888
|
EBITDA
|
-
|
-1.106
|
-12.98
|
-31.84
|
-36.81
|
-36.13
|
EBIT
1 |
-6.668
|
-2.683
|
-18.99
|
-31.97
|
-37.15
|
-36.62
|
Operating Margin
|
-648.34%
|
-34.6%
|
-
|
-9,265.8%
|
-1,045.33%
|
-1,939.51%
|
Earnings before Tax (EBT)
1 |
-6.669
|
-3.748
|
-23.83
|
-32.33
|
-37.27
|
-36.86
|
Net income
1 |
-6.669
|
-3.748
|
-23.83
|
-32.33
|
-37.27
|
-36.86
|
Net margin
|
-648.44%
|
-48.33%
|
-
|
-9,372.17%
|
-1,048.68%
|
-1,952.33%
|
EPS
2 |
-0.3179
|
-0.1674
|
-1.017
|
-1.203
|
-1.164
|
-1.072
|
Free Cash Flow
1 |
-22.29
|
-23.24
|
-28.89
|
-19.17
|
-31.11
|
-22.63
|
FCF margin
|
-2,167.47%
|
-299.68%
|
-
|
-5,557.79%
|
-875.42%
|
-1,198.41%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/25/18
|
4/25/19
|
4/22/20
|
4/16/21
|
4/26/22
|
4/25/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
15.3
|
26.1
|
7.56
|
36.1
|
34
|
1.26
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-22.3
|
-23.2
|
-28.9
|
-19.2
|
-31.1
|
-22.6
|
ROE (net income / shareholders' equity)
|
-5.56%
|
-2.62%
|
-15.3%
|
-111%
|
-81.6%
|
-115%
|
ROA (Net income/ Total Assets)
|
-3.31%
|
-1.14%
|
-7.38%
|
-52.8%
|
-42.3%
|
-56.2%
|
Assets
1 |
201.5
|
328.8
|
322.7
|
61.24
|
88.11
|
65.63
|
Book Value Per Share
2 |
6.070
|
6.880
|
6.270
|
1.440
|
1.430
|
0.4400
|
Cash Flow per Share
2 |
0.7300
|
1.130
|
0.3100
|
1.220
|
1.000
|
0.1500
|
Capex
|
-
|
-
|
0.29
|
0.61
|
0.74
|
0.05
|
Capex / Sales
|
-
|
-
|
-
|
177.97%
|
20.71%
|
2.75%
|
Announcement Date
|
4/25/18
|
4/25/19
|
4/22/20
|
4/16/21
|
4/26/22
|
4/25/23
|
|
1st Jan change
|
Capi.
|
---|
| +57.41% | 1.06M | | -1.17% | 102B | | +2.87% | 96.09B | | +2.13% | 22.28B | | -14.77% | 21.4B | | -8.79% | 18.14B | | -39.98% | 17.02B | | -13.21% | 16.09B | | +8.55% | 13.83B | | +35.75% | 11.97B |
Bio Therapeutic Drugs
|